Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$371.67 -1.7%	$308.95	$130.50 ▼ $382.54	$11.15B	0.53	379,822 shs	309,001 shs
ONC BeOne Medicines	$284.97 -1.7%	$290.36	$239.25 ▼ $385.22	$31.82B	0.49	288,115 shs	325,154 shs
RVMD Revolution Medicines	$187.28 -2.8%	$153.42	$34.00 ▼ $193.10	$40.95B	1.4	3.25 million shs	4.00 million shs
TEVA Teva Pharmaceutical Industries	$33.94 +1.9%	$33.80	$14.99 ▼ $37.35	$38.30B	0.84	5.92 million shs	5.19 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	-1.71%	+9.25%	+20.27%	+43.55%	+170.38%
ONC BeOne Medicines	-1.73%	+3.20%	-1.02%	-7.61%	+17.72%
RVMD Revolution Medicines	-2.77%	+10.48%	+18.92%	+89.86%	+409.05%
TEVA Teva Pharmaceutical Industries	+2.21%	+2.34%	-3.93%	+12.16%	+102.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$371.67 -1.7%	$308.95	$130.50 ▼ $382.54	$11.15B	0.53	379,822 shs	309,001 shs
ONC BeOne Medicines	$284.97 -1.7%	$290.36	$239.25 ▼ $385.22	$31.82B	0.49	288,115 shs	325,154 shs
RVMD Revolution Medicines	$187.28 -2.8%	$153.42	$34.00 ▼ $193.10	$40.95B	1.4	3.25 million shs	4.00 million shs
TEVA Teva Pharmaceutical Industries	$33.94 +1.9%	$33.80	$14.99 ▼ $37.35	$38.30B	0.84	5.92 million shs	5.19 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	-1.71%	+9.25%	+20.27%	+43.55%	+170.38%
ONC BeOne Medicines	-1.73%	+3.20%	-1.02%	-7.61%	+17.72%
RVMD Revolution Medicines	-2.77%	+10.48%	+18.92%	+89.86%	+409.05%
TEVA Teva Pharmaceutical Industries	+2.21%	+2.34%	-3.93%	+12.16%	+102.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	2.83	Moderate Buy	$340.56	-8.37% Downside
ONC BeOne Medicines	2.93	Moderate Buy	$390.00	36.86% Upside
RVMD Revolution Medicines	3.00	Buy	$134.50	-28.18% Downside
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.78	23.11% Upside

Current Analyst Ratings Breakdown

Latest KRYS, RVMD, TEVA, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$179.00 ➝ $210.00
6/29/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$183.00 ➝ $235.00
6/18/2026	KRYS Krystal Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$306.00 ➝ $403.00
6/16/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
6/16/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$310.00 ➝ $361.00
6/4/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/2/2026	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$425.00 ➝ $436.00
6/2/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$165.00 ➝ $182.00
6/1/2026	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$169.00 ➝ $195.00
6/1/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/1/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$165.00 ➝ $195.00

(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$389.13M	28.16	$7.16 per share	51.88	$42.06 per share	8.84
ONC BeOne Medicines	$5.34B	5.85	$3.84 per share	74.19	$39.77 per share	7.17
RVMD Revolution Medicines	$11.58M	3,438.32	N/A	N/A	$8.44 per share	22.19
TEVA Teva Pharmaceutical Industries	$17.26B	2.26	$3.80 per share	8.93	$6.88 per share	4.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$204.83M	$7.48	49.69	35.36	N/A	53.92%	19.25%	17.62%	8/3/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$4.47	63.75	26.99	N/A	8.94%	12.06%	6.69%	N/A
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-83.22%	-59.06%	8/5/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	25.52	11.16	4.07	9.01%	43.53%	8.19%	7/29/2026 (Estimated)

Latest KRYS, RVMD, TEVA, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	-$2.29	-$0.46	-$2.29	$2.43 million	N/A
5/4/2026	Q1 2026	KRYS Krystal Biotech	$1.45	$1.83	+$0.38	$1.83	$112.11 million	$116.36 million
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
4/1/2026	Q1 2026	ONC BeOne Medicines	N/A	$0.25	N/A	$1.95	N/A	$1.51 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	9.46	9.06
ONC BeOne Medicines	0.20	3.64	3.27
RVMD Revolution Medicines	0.19	6.80	6.80
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
ONC BeOne Medicines	48.55%
RVMD Revolution Medicines	94.34%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.10%
ONC BeOne Medicines	6.19%
RVMD Revolution Medicines	7.60%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	210	29.48 million	25.62 million	Optionable
ONC BeOne Medicines	12,000	109.72 million	102.93 million	N/A
RVMD Revolution Medicines	250	212.60 million	196.44 million	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

KRYS, RVMD, TEVA, and ONC Headlines

Recent News About These Companies

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

June 30 at 12:26 PM | finance.yahoo.com

Yelin Lapidot Holdings Management Ltd. Decreases Position in Teva Pharmaceutical Industries Ltd. $TEVA

June 29 at 6:24 AM | marketbeat.com

Teva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition

June 28 at 11:01 AM | seekingalpha.com

EU approves Teva bid for Allergan's generics with conditions

June 27, 2026 | ca.finance.yahoo.com

Union Bancaire Privee UBP SA Sells 44,839 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

June 27, 2026 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLC

June 27, 2026 | marketbeat.com

Assenagon Asset Management S.A. Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

June 26, 2026 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Stake Increased by SG Americas Securities LLC

June 25, 2026 | marketbeat.com

Hsbc Holdings PLC Lowers Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

June 25, 2026 | marketbeat.com

Deepti Hegde appointed as Director HR at Teva Pharmaceuticals

June 25, 2026 | peoplematters.inP

Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?

June 24, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justified

June 24, 2026 | finance.yahoo.com

Is Ecopipam’s FDA Filing Reshaping the Investment Case For Teva Pharmaceutical Industries (TEVA)?

June 23, 2026 | finance.yahoo.com

Stock Traders Purchase Large Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)

June 23, 2026 | marketbeat.com

Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth

June 23, 2026 | zacks.com

New Austedo Data Gives Teva (TEVA) Another Reason for Optimism

June 22, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Brokerages

June 22, 2026 | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 22, 2026 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Gains Fresh Attention After Market Retreat

June 21, 2026 | kalkinemedia.comK

Teva Pharmaceutical Industries Ltd: Teva Releases Q2 2026 Aide Memoire

June 19, 2026 | finanznachrichten.de

Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome

June 19, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRYS, RVMD, TEVA, and ONC Company Descriptions

Krystal Biotech NASDAQ:KRYS

$371.67 -6.48 (-1.71%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$374.27 +2.60 (+0.70%)

As of 06/30/2026 07:49 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

BeOne Medicines NASDAQ:ONC

$284.97 -5.02 (-1.73%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$285.00 +0.03 (+0.01%)

As of 06/30/2026 06:52 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Revolution Medicines NASDAQ:RVMD

$187.28 -5.34 (-2.77%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$187.28 0.00 (0.00%)

As of 06/30/2026 07:48 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries NYSE:TEVA

$33.94 +0.63 (+1.88%)

Closing price 06/30/2026 03:59 PM Eastern

Extended Trading

$33.83 -0.11 (-0.32%)

As of 06/30/2026 07:44 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRYS, RVMD, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRYS, RVMD, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRYS, RVMD, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRYS, RVMD, TEVA, and ONC Company Descriptions

Krystal Biotech NASDAQ:KRYS

BeOne Medicines NASDAQ:ONC

Revolution Medicines NASDAQ:RVMD

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRYS, RVMD, TEVA, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRYS, RVMD, TEVA, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRYS, RVMD, TEVA, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRYS, RVMD, TEVA, and ONC Company Descriptions

Krystal Biotech NASDAQ:KRYS

BeOne Medicines NASDAQ:ONC

Revolution Medicines NASDAQ:RVMD

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools